For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Nanogen, Inc.

USPTO Granted Patents = 100

CIPO Patents = 1

Trademarks = 4

Forward Citations = 6,713

Loading Chart...

Loading Chart...

86 inventors (with patents filed for the assignee):

Michael James Heller (37 out of 47 patents)

Eugene Tu (20 out of 64 patents)

Donald E Ackley (17 out of 68 patents)

4. Paul David Swanson (14 out of 72 patents)

5. George Jackowski (12 out of 71 patents)

6. Ronald George Sosnowski (12 out of 16 patents)

7. James P O'Connell (11 out of 17 patents)

8. Edward L Sheldon (11 out of 24 patents)

9. John G Marshall (9 out of 43 patents)

10. Carl Frederick Edman (8 out of 23 patents)

11. William Frank Butler (8 out of 16 patents)

12. Gregory T A Kovacs (7 out of 33 patents)

13. Lei Wu (6 out of 31 patents)

14. Michael I Nerenberg (6 out of 15 patents)

15. Scott O Graham (6 out of 7 patents)

Core Competencies:

Biopolymer Markers

Electronic Matrix Devices

Active Biological Operations

Bioelectronic Microchip

Multiplexed Active Biologic Array

Diagnostic Devices

Molecular Biological Analysis

Enzymatic Reactions

Genetic Mutations

Cardiac Mortality Prediction

Dielectrophoretic Separation

Hybridization Techniques

100 patents: Sort by Forward Citations

1. 7655424 - Method for diagnosing and distinguishing stroke and diagnostic devices for use therein (2010-02-02),

2. 7601493 - Methods and apparatus for screening and detecting multiple genetic mutations (2009-10-13),

3. 7601301 - Multiplexed active biologic array (2009-10-13),

4. 7597932 - Mesoporous permeation layers for use on active electronic matrix devices (2009-10-06),

5. 7582421 - Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchip (2009-09-01),

6. 7527939 - Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP (2009-05-05),

7. 7425308 - Systems for the active electronic control of biological reactions (2008-09-16),

8. 7329501 - Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance (2008-02-12),

9. 7315784 - Network for evaluating data obtained in a biochip measurement device (2008-01-01),

10. 7314762 - Apolipoprotein biopolymer markers indicative of insulin resistance (2008-01-01),

11. 7314717 - Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons (2008-01-01),

12. 7314708 - Method and apparatus for electronic synthesis of molecular structures (2008-01-01),

13. 7314542 - Methods and materials for optimization of electronic transportation and hybridization reactions (2008-01-01),

14. 7300757 - Electronic systems and component devices for macroscopic and microscopic molecular biological reaction, analyses, and diagnostics (2007-11-27),

15. 7294688 - Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons (2007-11-13),

Nanogen, Inc. is a biotechnology company focused on researching, developing, and marketing innovative molecular diagnostic products. The company specializes in creating rapid, accurate, and reliable tests for a wide range of medical conditions, including infectious diseases, genetic disorders, and cancer. Nanogen's mission is to improve healthcare outcomes by providing advanced diagnostic tools that enable early detection, personalized medicine, and effective treatment strategies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

100 Patents

#63 in San Diego, CA

#856 in California

#3,647 in US

#7,554 in the World

San Diego, CA, United States of America

Nanogen, Inc.

Forward Citations = 6,713

86 inventors:

Michael James Heller (37 out of 47 patents)

Eugene Tu (20 out of 64 patents)

Donald E Ackley (17 out of 68 patents)

4. Paul David Swanson (14 out of 72 patents)

5. George Jackowski (12 out of 71 patents)

Please report any incorrect information to support@idiyas.com

Loading…